Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis

Table 2 Clinical and virological characteristics of the 12 HCV/HIV co-infected patients.

Patient	Age	Gender	Genotype	Serum HCV RNA (log₁₀)	Diversity		Complexity
					Taq	HF-2	Taq	HF-2
1	49	F	1a	6.37	0.9856	0.9616	4	5
2	40	M	1a	5.96	0.9987	0.9978	2	2
3	36	F	1b	5.53	1.0000	1.0000	1	1
4	38	M	1a	6.75	0.9313	0.9715	8	11
5	42	M	1a	6.94	1.0000	1.0000	1	1
6	40	M	1b	5.55	0.9912	0.9997	5	2
7	41	M	1a	6.39	0.9909	1.0000	6	1
8	45	F	1a	6.25	0.9856	0.9468	4	7
9	47	M	1a	5.68	0.9945	0.9996	2	2
10	41	M	1a	5.92	0.9575	0.9430	10	10
11	61	F	1a	6.83	0.9389	0.9283	7	6
12	51	M	1a	6.99	0.9890	0.9638	2	7
AVG	44.2			6.53	0.9803	0.9760	4.33	5.0

HCV genotypes were determined by INNO-LiPA, while HCV RNA was quantified with the Roche COBAS Monitor assay, and is expressed a log₁₀IU/mL. QS heterogeneity was assessed using the clonal frequency analysis (CFA) technique. Diversity scores represent the average heteroduplex mobility ratios (HMR) for either Taq or HF-2 enzymes. Complexity scores represent the total number of distinct gel shift variants analyzed by CFA. AVG represents average.

ISSN: 1743-422X